Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Andreas Hochhaus, Neil P. Shah et al.|Blood|2013Cited by 391
FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemiaLaura Ondrišová, Marek Mráz, Václav Šeda et al.|Journal of Clinical Investigation|2024Cited by 12